A Phase 1/2 interventional study of Fruquintinib and Tislelizumab in Triple Negative Breast Cancer, Endometrial Cancer and Solid Tumor, Unspecified, Adult, sponsored by Hutchmed. Terminated at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Hutchmed · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tislelizumab in Triple Negative Breast Neoplasms — 6 open to participants now, 8 under way, none of them phase 3. tislelizumab · Triple Negative Breast Neoplasms.
Among the 12 studies testing tislelizumab in Triple Negative Breast Neoplasms, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 1/2, and was the 2nd registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →6 of the 12 studies testing tislelizumab in Triple Negative Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18–70 · Women only
Huihua Xiong · Sites in China
Ages 18–70 · Women only
Sichuan Provincial People's Hospital · Sites in China
Ages 18–75 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Women only
National University Hospital, Singapore · Sites in Singapore
Ages 21+
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12
First in 2020; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 65 across the 12 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 9 most frequent:
This study is registered under Hutchmed, one of the names counted as HUTCHMED. Under that name alone:
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
HUTCHMED has 2 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing tislelizumab in Triple Negative Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538896Zhejiang Cancer HospitalTislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | 2026-12 |
| NCT04501523Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing tislelizumab in Triple Negative Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2).
The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 6-12 patients with locally advanced or metastatic solid tumors will be enrolled to receive fruquintinib in combination with tislelizumab and assessed for DLTs during the 28-day DLT observation period
Drug: Fruquintinib · Drug: Tislelizumab
Patients will be enrolled to one of the following expansion cohorts: * Cohort A: TNBC (immuno-oncology \[IO\]-treated in the metastatic setting) * Cohort B: TNBC (IO-Naïve in the metastatic setting) * Cohort C: EC * Cohort D: MSS CRC
Drug: Fruquintinib · Drug: Tislelizumab
Oral VEGFR inhibitor
Also known as: HMPL-013
PD-1 inhibitor
Also known as: BGB-A317
Part 1: Number of Patients With Dose-Limiting Toxicities (DLTs)
According to National Cancer Institute Common Terminology Criteria for Adverse Events(AEs) v5.0, DLT was defined as any 1 of following toxicities during DLT assessment window and considered by Investigator to be related to 1 or more study treatments:a)Hematologic: grade(G) 4 neutropenia lasting \>7 days, G ≥3 febrile neutropenia, G 3 thrombocytopenia with clinically significant bleeding, G 4 thrombocytopenia, G ≥4 anemia.b) Non-hematologic:all G ≥3 non-hematologic toxicities except:G 3 endocrinopathy controlled by hormonal replacement with no hospitalization and resolved to G ≤1 within 7 days, G 3 nausea/vomiting or diarrhea for \<72 hours with antiemetic and supportive care, G 3 fatigue for \<1 week, G ≥3 electrolyte abnormality lasting up to 72 hours and resolving with treatment, G 3 rash returning to baseline or G ≤1 within 7 days with treatment,G ≥3 amylase or lipase elevation without symptoms of pancreatitis,G 3 hypertension returning to baseline or G≤1 within 7 days with treatment.
Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (cycle duration: 4 weeks)
Part 1: Recommended Phase 2 Dose (RP2D) of Fruquintinib in Combination With Tislelizumab
The RP2D of fruquintinib in combination with tislelizumab based on the safety and tolerability assessments in Part 1 patients.
Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (cycle duration: 4 weeks)
Part 2: Objective Response Rate (ORR)
The ORR was defined as the percentage of patients with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 millimeters (mm). The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Part 1: Objective Response Rate
The ORR was defined as the percentage of patients with a confirmed BOR of CR or PR as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Parts 1 and 2: Progression-free Survival (PFS)
PFS was defined as the time from the start of study treatment until the first radiographic documentation of objective progression as assessed by the investigator using RECIST v1.1, or death from any cause. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Parts 1 and 2: Disease Control Rate (DCR)
The DCR was defined as the percentage of patients with a BOR of CR, PR, or stable disease (SD) lasting for at least 7 weeks as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Parts 1 and 2: Clinical Benefit Rate (CBR)
The CBR was defined as the percentage of patients with a BOR of CR, PR, or durable SD (i.e., lasting for at least 6 months) as determined by the investigator using RECIST v1.1. Durable SD was SD for at least 6 months. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Parts 1 and 2: Duration of Response (DoR)
The DoR was defined as the time from the first occurrence of PR or CR by RECIST v1.1, whichever came first until PD or death. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Parts 1 and 2: Overall Survival (OS)
The OS was defined as the time from start of study treatment until the date of death due to any cause.
Time frame: From the first dose of study treatment (Day 1) up to date of death due to any cause, up to a maximum of approximately 34 months
Parts 1 and 2: Plasma Concentrations of Fruquintinib and Metabolite M11
Blood samples were collected at the specified timepoints to determine plasma concentrations of fruquintinib and metabolite M11.
Time frame: Pre-dose on Days 1, 8, 15, 21 of Cycle 1 and on Day 1 of Cycles 2, 4, 7, 13; 2 to 4 hours post-dose on Days 1 and 21 of Cycle 1 (cycle duration: 4 weeks)
Parts 1 and 2: Serum Concentrations of Tislelizumab
Blood samples were collected at the specified timepoints to determine serum concentrations of tislelizumab.
Time frame: Pre-infusion on Day 1 of Cycles 1, 2, 4, 7, 13; at end of infusion on Day 1 of Cycles 1 and 4; on Days 8, 15, and 21 of Cycle 1 (cycle duration: 4 weeks)
Parts 1 and 2: Number of Patients With Antidrug Antibodies (ADAs) to Tislelizumab
Blood samples were collected at the specified timepoints to detect ADAs to tislelizumab. Treatment-induced ADA was defined as ADA negative at baseline and ADA positive post-baseline. Treatment-boosted ADA was defined as ADA positive at baseline that was boosted to a 4-fold or higher-level following treatment administration.
Time frame: From the first dose of study treatment (Day 1) up to end of treatment, up to approximately 17 months for Part 1 and 20 months for Part 2
Part 2: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation
An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. An AE was considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was an abnormal pregnancy outcome in a child born to a female patient/female partner of a male patient exposed to study treatment or was an important medical event. TEAEs were AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration.
Time frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 21 months
Part 2: Change From Baseline in Programmed Death-Ligand 1 (PD-L1) Expression
Expression of PD-L1 biomarker was planned to be assessed in tumor tissues of the patients. Baseline was defined as the last non-missing assessment prior to the first administration of any study treatment (whichever occurred first), including scheduled and unscheduled visits, unless otherwise specified.
Time frame: Baseline (Day 1) up to end of treatment, up to approximately 20 months
This phase 1b/2, 2-part, open-label study was conducted in patients with advanced or metastatic solid tumors.
| Milestone | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 | 0 |
| Completed | 6 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Started | 0 | 1 | 11 | 1 | 39 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 11 | 1 | 39 |
| Withdrew: Death | 0 | 1 | 8 | 0 | 20 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 10 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Sponsor terminated study | 0 | 0 | 3 | 1 | 4 |
According to National Cancer Institute Common Terminology Criteria for Adverse Events(AEs) v5.0, DLT was defined as any 1 of following toxicities during DLT assessment window and considered by Investigator to be related to 1 or more study treatments:a)Hematologic: grade(G) 4 neutropenia lasting \>7 days, G ≥3 febrile neutropenia, G 3 thrombocytopenia with clinically significant bleeding, G 4 thrombocytopenia, G ≥4 anemia.b) Non-hematologic:all G ≥3 non-hematologic toxicities except:G 3 endocrinopathy controlled by hormonal replacement with no hospitalization and resolved to G ≤1 within 7 days, G 3 nausea/vomiting or diarrhea for \<72 hours with antiemetic and supportive care, G 3 fatigue for \<1 week, G ≥3 electrolyte abnormality lasting up to 72 hours and resolving with treatment, G 3 rash returning to baseline or G ≤1 within 7 days with treatment,G ≥3 amylase or lipase elevation without symptoms of pancreatitis,G 3 hypertension returning to baseline or G≤1 within 7 days with treatment.
| Participants | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) |
|---|---|
| Part 1: Number of Patients With Dose-Limiting Toxicities (DLTs) | 1 |
The RP2D of fruquintinib in combination with tislelizumab based on the safety and tolerability assessments in Part 1 patients.
| mg | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) |
|---|---|
| Part 1: Recommended Phase 2 Dose (RP2D) of Fruquintinib in Combination With Tislelizumab | 5 |
The ORR was defined as the percentage of patients with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 millimeters (mm). The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| percentage of patients | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|
| Part 2: Objective Response Rate (ORR) | 0 (NA to NA) | 27.3 (6.0 to 61.0) | 0 (NA to NA) | 5.1 (0.6 to 17.3) |
The ORR was defined as the percentage of patients with a confirmed BOR of CR or PR as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| percentage of patients | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) |
|---|---|
| Part 1: Objective Response Rate | 16.7 (0.4 to 64.1) |
PFS was defined as the time from the start of study treatment until the first radiographic documentation of objective progression as assessed by the investigator using RECIST v1.1, or death from any cause. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.
| months | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Parts 1 and 2: Progression-free Survival (PFS) | 3.8 (1.8 to NA) | NA (NA to NA) | 5.0 (1.8 to 7.4) | 5.5 (NA to NA) | 3.6 (2.0 to 5.6) |
The DCR was defined as the percentage of patients with a BOR of CR, PR, or stable disease (SD) lasting for at least 7 weeks as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.
| percentage of patients | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Parts 1 and 2: Disease Control Rate (DCR) | 50.0 (11.8 to 88.2) | 0 (NA to NA) | 72.7 (39.0 to 94.0) | 100 (2.5 to 100) | 53.8 (37.2 to 69.9) |
The CBR was defined as the percentage of patients with a BOR of CR, PR, or durable SD (i.e., lasting for at least 6 months) as determined by the investigator using RECIST v1.1. Durable SD was SD for at least 6 months. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.
| percentage of patients | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Parts 1 and 2: Clinical Benefit Rate (CBR) | 16.7 (0.4 to 64.1) | 0 (NA to NA) | 27.3 (6.0 to 61.0) | 0 (NA to NA) | 20.5 (9.3 to 36.5) |
The DoR was defined as the time from the first occurrence of PR or CR by RECIST v1.1, whichever came first until PD or death. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.
| months | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Parts 1 and 2: Duration of Response (DoR) | 14.9 (NA to NA) | — | 14.9 (6.0 to NA) | — | NA (NA to NA) |
The OS was defined as the time from start of study treatment until the date of death due to any cause.
| months | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Parts 1 and 2: Overall Survival (OS) | 16.4 (12.0 to NA) | 25.8 (NA to NA) | 14.1 (5.0 to NA) | NA (NA to NA) | 10.2 (7.1 to 11.7) |
Blood samples were collected at the specified timepoints to determine plasma concentrations of fruquintinib and metabolite M11.
| nanograms per milliliter | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Fruquintinib: Cycle 1 Day 1: Pre-dose | 0 ± 0 | — | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Fruquintinib: Cycle 1 Day 1: 2 to 4 hours post-dose | 5.49 ± NA | — | 56.2 ± 52.9 | 125 ± NA | 70.7 ± 34.3 |
| Fruquintinib: Cycle 1 Day 8: Pre-dose | — | — | 222 ± 29.0 | — | 195 ± 57.0 |
| Fruquintinib: Cycle 1 Day 15: Pre-dose | — | — | 240 ± 72.7 | 263 ± NA | 177 ± 37.7 |
| Fruquintinib: Cycle 1 Day 21: Pre-dose | 252 ± NA | — | 216 ± 59.5 | — | 186 ± 51.4 |
| Fruquintinib: Cycle 1 Day 21: 2 to 4 hours post-dose | 327 ± NA | — | 327 ± NA | — | 267 ± 66.4 |
| Fruquintinib: Cycle 2 Day 1: Pre-dose | — | — | 23.2 ± 15.3 | 15.2 ± NA | 17.0 ± 17.7 |
| Fruquintinib: Cycle 4 Day 1: Pre-dose | — | — | 5.12 ± NA | — | 15.3 ± 8.89 |
| Fruquintinib: Cycle 7 Day 1: Pre-dose | — | — | — | — | 28.6 ± 19.1 |
| Fruquintinib: Cycle 13 Day 1: Pre-dose | — | — | — | — | 12.3 ± NA |
| M11: Cycle 1 Day 1: Pre-dose | 0 ± 0 | — | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| M11: Cycle 1 Day 1: 2 to 4 hours post-dose | 0 ± 0 | — | 0.415 ± 0.643 | 2.71 ± NA | 0.413 ± 0.766 |
| M11: Cycle 1 Day 8: Pre-dose | — | — | 84.2 ± 53.5 | — | 60.7 ± 34.7 |
| M11: Cycle 1 Day 15: Pre-dose | — | — | 87.3 ± 32.4 | 139 ± NA | 74.6 ± 45.9 |
| M11: Cycle 1 Day 21: Pre-dose | 148 ± NA | — | 106 ± 40.0 | — | 66.1 ± 28.0 |
| M11: Cycle 1 Day 21: 2 to 4 hours post-dose | 124 ± NA | — | 124 ± NA | — | 69.1 ± 25.4 |
| M11: Cycle 2 Day 1: Pre-dose | — | — | 30.8 ± 12.6 | 40.5 ± NA | 20.5 ± 14.4 |
| M11: Cycle 4 Day 1: Pre-dose | — | — | 16.6 ± NA | — | 19.3 ± 10.4 |
| M11: Cycle 7 Day 1: Pre-dose | — | — | — | — | 31.4 ± 8.60 |
| M11: Cycle 13 Day 1: Pre-dose | — | — | — | — | 11.7 ± NA |
Blood samples were collected at the specified timepoints to determine serum concentrations of tislelizumab.
| micrograms per milliliter | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Cycle 1 Day 1: Pre-infusion | 0 ± 0 | — | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Cycle 1 Day 1: End of infusion | 105 ± 23.5 | — | 101 ± 22.7 | 74.0 ± NA | 78.3 ± 19.9 |
| Cycle 1 Day 8 | 49.5 ± 12.7 | — | 54.4 ± 15.1 | 45.2 ± NA | 39.2 ± 10.0 |
| Cycle 1 Day 15 | 34.3 ± 11.2 | — | 31.4 ± 7.63 | 36.7 ± NA | 27.7 ± 8.72 |
| Cycle 1 Day 21 | 27.3 ± 13.1 | — | 28.1 ± 6.58 | — | 20.3 ± 5.58 |
| Cycle 2 Day 1: Pre-infusion | 22.2 ± 8.27 | — | 19.3 ± 10.5 | 21.5 ± NA | 15.1 ± 5.14 |
| Cycle 4 Day 1: Pre-infusion | 29.9 ± 11.8 | — | 41.0 ± 15.5 | 46.6 ± NA | 25.1 ± 8.64 |
| Cycle 4 Day 1: End of infusion | 158 ± 47.6 | — | 172 ± 7.78 | 137 ± NA | 114 ± 25.4 |
| Cycle 7 Day 1: Pre-infusion | 57.2 ± NA | — | 50.0 ± 31.0 | — | 35.5 ± 14.4 |
| Cycle 13 Day 1: Pre-infusion | 45.9 ± NA | — | 26.0 ± NA | — | 34.9 ± 7.32 |
Blood samples were collected at the specified timepoints to detect ADAs to tislelizumab. Treatment-induced ADA was defined as ADA negative at baseline and ADA positive post-baseline. Treatment-boosted ADA was defined as ADA positive at baseline that was boosted to a 4-fold or higher-level following treatment administration.
| Participants | Part 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|---|
| Treatment-Induced ADA | 2 | 0 | 3 | 0 | 10 |
| Treatment-Boosted ADA | 0 | 0 | 0 | 0 | 2 |
An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. An AE was considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was an abnormal pregnancy outcome in a child born to a female patient/female partner of a male patient exposed to study treatment or was an important medical event. TEAEs were AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration.
| Participants | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|
| TEAEs | 1 | 11 | 1 | 39 |
| TESAEs | 0 | 2 | 1 | 20 |
| TEAEs leading to fruquintinib treatment discontinuation | 1 | 1 | 1 | 9 |
| TEAEs leading to tislelizumab treatment discontinuation | 1 | 1 | 0 | 9 |
Expression of PD-L1 biomarker was planned to be assessed in tumor tissues of the patients. Baseline was defined as the last non-missing assessment prior to the first administration of any study treatment (whichever occurred first), including scheduled and unscheduled visits, unless otherwise specified.
No measurements were reported for this outcome.
Collected over Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 18 months for Part 1 and 21 months for Part 2. All-cause mortality (deaths) were collected from Day 1 up to end of follow up, approximately 34 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | 8/11 (72.7%) | 2/11 (18.2%) | 11/11 (100%) |
| Part 2: Cohort C: EC (IO-Naïve) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Part 2: Cohort D: MSS mCRC (IO-Naïve) | 20/39 (51.3%) | 20/39 (51.3%) | 39/39 (100%) |
| Event | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|
| HypertensionVascular disorders | 0/1 | 0/11 | 1/1 | 0/39 |
| ConstipationGastrointestinal disorders | 0/1 | 1/11 | 0/1 | 0/39 |
| Disease progressionGeneral disorders | 0/1 | 1/11 | 0/1 | 2/39 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/1 | 1/11 | 0/1 | 0/39 |
| Abdominal painGastrointestinal disorders | 0/1 | 0/11 | 0/1 | 3/39 |
| NauseaGastrointestinal disorders | 0/1 | 0/11 | 0/1 | 2/39 |
| VomitingGastrointestinal disorders | 0/1 | 0/11 | 0/1 | 2/39 |
| Urinary tract infectionInfections and infestations | 0/1 | 0/11 | 0/1 | 2/39 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/1 | 0/11 | 0/1 | 2/39 |
| Depressed level of consciousnessNervous system disorders | 0/1 | 0/11 | 0/1 | 2/39 |
| Event | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) |
|---|---|---|---|---|
| FatigueGeneral disorders | 0/1 | 5/11 | 1/1 | 26/39 |
| Gait disturbanceGeneral disorders | 1/1 | 0/11 | 0/1 | 0/39 |
| Platelet count decreasedInvestigations | 1/1 | 1/11 | 0/1 | 1/39 |
| DehydrationMetabolism and nutrition disorders | 1/1 | 0/11 | 0/1 | 3/39 |
| HypertensionVascular disorders | 1/1 | 4/11 | 1/1 | 13/39 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/1 | 5/11 | 1/1 | 5/39 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/1 | 0/11 | 1/1 | 1/39 |
| Memory impairmentNervous system disorders | 1/1 | 0/11 | 1/1 | 0/39 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 1/1 | 0/11 | 0/1 | 7/39 |
| Sinus bradycardiaCardiac disorders | 1/1 | 0/11 | 0/1 | 0/39 |
The safety analysis set (SAS) included all enrolled patients who received at least 1 dose of fruquintinib or tislelizumab. 1 patient enrolled in Part 1 was also included in Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) and 5 patients enrolled in Part 1 were also included in Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting).
| Age, Categorical(Participants) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 8 | 0 | 32 | 40 |
| >=65 years | 1 | 3 | 1 | 7 | 12 |
| Sex: Female, Male(Participants) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) | Total |
|---|---|---|---|---|---|
| Female | 1 | 11 | 1 | 12 | 25 |
| Male | 0 | 0 | 0 | 27 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 4 | 5 |
| Not Hispanic or Latino | 1 | 9 | 1 | 32 | 43 |
| Unknown or Not Reported | 0 | 1 | 0 | 3 | 4 |
| Race (NIH/OMB)(Participants) | Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) | Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting) | Part 2: Cohort C: EC (IO-Naïve) | Part 2: Cohort D: MSS mCRC (IO-Naïve) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 2 | 3 |
| White | 1 | 10 | 1 | 31 | 43 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 4 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Jun 2024, 34 months.
Results were first posted in Jul 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: HMPL-013 · Tislelizumab
Triple Negative Breast Neoplasms →